Literature DB >> 27308563

Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma.

Matthew Hellmann1, Naiyer Rizvi2, Jedd D Wolchok1, Timothy A Chan3.   

Abstract

The recent successes of immune checkpoint therapies have established a new era for the treatment of patients with cancer, yet the predictors of response remain largely undetermined. We recently demonstrated that the genomic landscape of lung cancers substantially influences the response to programmed cell death 1 receptor (PD-1) blockade, providing new insights into the molecular determinants of the response to immunotherapy.

Entities:  

Keywords:  Cancer; immunotherapy; lung; mutation

Year:  2015        PMID： 27308563      PMCID： PMC4845184          DOI： 10.1080/23723556.2015.1048929

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

Review 2.  Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers.

Authors:  Gerd P Pfeifer; Mikhail F Denissenko; Magali Olivier; Natalia Tretyakova; Stephen S Hecht; Pierre Hainaut
Journal:  Oncogene       Date:  2002-10-21       Impact factor: 9.867

3.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

Review 4.  Cancer genome landscapes.

Authors:  Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

5.  Genomic landscape of non-small cell lung cancer in smokers and never-smokers.

Authors:  Ramaswamy Govindan; Li Ding; Malachi Griffith; Janakiraman Subramanian; Nathan D Dees; Krishna L Kanchi; Christopher A Maher; Robert Fulton; Lucinda Fulton; John Wallis; Ken Chen; Jason Walker; Sandra McDonald; Ron Bose; David Ornitz; Donghai Xiong; Ming You; David J Dooling; Mark Watson; Elaine R Mardis; Richard K Wilson
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

6.  Comprehensive genomic characterization of squamous cell lung cancers.

Authors: 
Journal:  Nature       Date:  2012-09-09       Impact factor: 49.962

7.  Signatures of mutational processes in human cancer.

Authors:  Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Samuel A J R Aparicio; Sam Behjati; Andrew V Biankin; Graham R Bignell; Niccolò Bolli; Ake Borg; Anne-Lise Børresen-Dale; Sandrine Boyault; Birgit Burkhardt; Adam P Butler; Carlos Caldas; Helen R Davies; Christine Desmedt; Roland Eils; Jórunn Erla Eyfjörd; John A Foekens; Mel Greaves; Fumie Hosoda; Barbara Hutter; Tomislav Ilicic; Sandrine Imbeaud; Marcin Imielinski; Marcin Imielinsk; Natalie Jäger; David T W Jones; David Jones; Stian Knappskog; Marcel Kool; Sunil R Lakhani; Carlos López-Otín; Sancha Martin; Nikhil C Munshi; Hiromi Nakamura; Paul A Northcott; Marina Pajic; Elli Papaemmanuil; Angelo Paradiso; John V Pearson; Xose S Puente; Keiran Raine; Manasa Ramakrishna; Andrea L Richardson; Julia Richter; Philip Rosenstiel; Matthias Schlesner; Ton N Schumacher; Paul N Span; Jon W Teague; Yasushi Totoki; Andrew N J Tutt; Rafael Valdés-Mas; Marit M van Buuren; Laura van 't Veer; Anne Vincent-Salomon; Nicola Waddell; Lucy R Yates; Jessica Zucman-Rossi; P Andrew Futreal; Ultan McDermott; Peter Lichter; Matthew Meyerson; Sean M Grimmond; Reiner Siebert; Elías Campo; Tatsuhiro Shibata; Stefan M Pfister; Peter J Campbell; Michael R Stratton
Journal:  Nature       Date:  2013-08-14       Impact factor: 49.962

8.  Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas.

Authors:  Claire Palles; Jean-Baptiste Cazier; Kimberley M Howarth; Enric Domingo; Angela M Jones; Peter Broderick; Zoe Kemp; Sarah L Spain; Estrella Guarino; Estrella Guarino Almeida; Israel Salguero; Amy Sherborne; Daniel Chubb; Luis G Carvajal-Carmona; Yusanne Ma; Kulvinder Kaur; Sara Dobbins; Ella Barclay; Maggie Gorman; Lynn Martin; Michal B Kovac; Sean Humphray; Anneke Lucassen; Christopher C Holmes; David Bentley; Peter Donnelly; Jenny Taylor; Christos Petridis; Rebecca Roylance; Elinor J Sawyer; David J Kerr; Susan Clark; Jonathan Grimes; Stephen E Kearsey; Huw J W Thomas; Gilean McVean; Richard S Houlston; Ian Tomlinson
Journal:  Nat Genet       Date:  2012-12-23       Impact factor: 38.330

9.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962

10.  Comprehensive molecular profiling of lung adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-09       Impact factor: 49.962
  10 in total
  18 in total

1.  Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.

Authors:  Barbara Melosky; Rosalyn Juergens; Vera Hirsh; Deanna McLeod; Natasha Leighl; Ming-Sound Tsao; Paul B Card; Quincy Chu
Journal:  Oncologist       Date:  2019-05-28

Review 2.  Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?

Authors:  Matthew Evans; Brendan O'Sullivan; Matthew Smith; Philippe Taniere
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 3.  Atezolizumab for the treatment of non-small cell lung cancer.

Authors:  Fernando C Santini; Charles M Rudin
Journal:  Expert Rev Clin Pharmacol       Date:  2017-07-27       Impact factor: 5.045

Review 4.  Immune checkpoint inhibitors and small cell lung cancer: what's new?

Authors:  Sabine Schmid; Martin Früh
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 5.  PD-1/PD-L1 Axis in Lung Cancer.

Authors:  Fernando C Santini; Matthew D Hellmann
Journal:  Cancer J       Date:  2018 Jan/Feb       Impact factor: 3.360

Review 6.  DNA repair defects and implications for immunotherapy.

Authors:  Katherine M Bever; Dung T Le
Journal:  J Clin Invest       Date:  2018-10-01       Impact factor: 14.808

7.  Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response.

Authors:  Fan Shi; Jin Su; Juan Wang; Zi Liu; Tao Wang
Journal:  Mol Cell Biochem       Date:  2020-11-03       Impact factor: 3.396

Review 8.  Molecular chess? Hallmarks of anti-cancer drug resistance.

Authors:  Ian A Cree; Peter Charlton
Journal:  BMC Cancer       Date:  2017-01-05       Impact factor: 4.430

9.  PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung.

Authors:  Urska Janzic; Izidor Kern; Andrej Janzic; Luka Cavka; Tanja Cufer
Journal:  Radiol Oncol       Date:  2017-09-14       Impact factor: 2.991

10.  Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.

Authors:  Jung Han Kim; Hyeong Su Kim; Bum Jun Kim
Journal:  Oncotarget       Date:  2017-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.